Put companies on watchlist
Novavax
ISIN: US6700021040
WKN: 898527
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Novavax · ISIN: US6700021040 · PR Newswire (ID: 20250730PH40228)
30 July 2025 02:00PM

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025


GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows:

Conference call details:



Date:

August 6, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

Register Here

Dial-in number:

(888) 880-3330 (Domestic) or



(+1) (646) 357-8766 (International)

Webcast:

ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

Replay details:



Date:

Available starting at 11:30 a.m. U.S. ET, August 6, 2025, until 11:59 p.m. U.S. ET, August 13, 2025

Dial-in number:

(800) 770-2030 (Domestic) or



(+1) (609) 800-9909 (International)

Passcode:

3041984#

Webcast:

ir.novavax.com/events, until September 5, 2025

About Novavax

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.

Contacts: 

Investors

Luis Sanay, CFA

240-268-2022

ir@novavax.com

Media

Giovanna Chandler

844-264-8571

media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-second-quarter-2025-financial-results-on-august-6-2025-302516855.html

SOURCE Novavax, Inc.

Visual performance / price development - Novavax
Smart analysis and research tools can be found here.
MIC: XNAS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942